Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q1 2024 call → NOThe question asks whether management describes that the company's successive engagements of the same kind are coming in at progressively larger size — i.e., that the deals/contracts/projects it is landing now are individually bigger, broader, or longer than before for the same offering. Looking through the transcript, I need to find any statement from management about deal size, contract size, order size, etc., escalating over time. The transcript discusses: - Sales growth at various divisions (American Income, Liberty National, Family Heritage, Direct to Consumer, United American) - Agent count growth - Premium growth - Investment yields - Share repurchases - An M&A opportunity that was evaluated and then walked away from The M&A discussion: management mentions they were evaluating a potential acquisition, paused share repurchases, and then decided not to pursue it. They don't describe it as part of an escalating pattern of deal sizes. They say it was "a little bit bigger than some of them that we've done recently" but this is about a potential acquisition, not about the company's own business engagements being won at larger sizes. There's no discussion of the company's own products, policies, contracts, or projects being won at progressively larger sizes. The business is insurance - selling policies. The discussion is about premium growth, agent counts, sales volumes, but nothing about the individual size of policies or engagements escalating. The question is about whether the company's own repeatable business (selling insurance policies) is coming in at progressively larger unit sizes. Nothing in the transcript suggests this. Management talks about sales growth driven by agent count, but not about larger individual policies or deals. So the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.